Over the last 25 years, the evolution of anti-obesity drugs from Xenical to groundbreaking GLP-1/GIP agonists like Wegovy and Zepbound has been significant. These modern medications offer hope with greater BMI reductions, although challenges such as accessibility and cost remain. Understanding this progression is crucial in combating the obesity epidemic.